FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Articles|May 11, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of May 11, 2022
Author(s)Sydney Jennings
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, May 11, 2022, at 2:41 PM, EDT:
46.1% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
• 66.3% of total US population
• 70.5% of US population aged ≥5 years
• 74.8% of US population aged ≥12 years
• 76.3% of US population aged ≥18 years
• 90.6% of US population aged ≥65 years
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, May 11, 2022 at 3:20 PM, EDT, there have been:
• 82 141 918 confirmed cases and
• 998 305 deaths
• 998 305 deaths
In the past 28 days, the 3 states with the most new cases are:
1. New York: 206 658
2. California: 173 199
3. Illinois:102 421
2. California: 173 199
3. Illinois:102 421
Deaths: California has the highest number of deaths due to COVID-19 with 90 615 reported fatalities, followed by Texas with 88 191 and Florida with 74 113.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 519 151 423 confirmed cases, 6 256 917 deaths, and 11 395 631 794 vaccine doses administered.
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
3
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5